Maxwell Skor
Stock Analyst at Morgan Stanley
(2.85)
# 1,852
Out of 5,017 analysts
6
Total ratings
80%
Success rate
20.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Equal-Weight | $126 → $144 | $163.94 | -12.16% | 1 | Aug 21, 2025 | |
| ASND Ascendis Pharma | Assumes: Overweight | $250 | $208.43 | +19.94% | 1 | Jul 3, 2025 | |
| SANA Sana Biotechnology | Assumes: Overweight | $12 | $4.35 | +176.18% | 1 | Jul 3, 2025 | |
| TCRX TScan Therapeutics | Assumes: Overweight | $10 | $2.20 | +354.55% | 1 | Mar 14, 2025 | |
| IVVD Invivyd | Maintains: Overweight | $9.5 → $3.55 | $1.88 | +88.83% | 2 | Nov 20, 2024 |
Insmed
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $126 → $144
Current: $163.94
Upside: -12.16%
Ascendis Pharma
Jul 3, 2025
Assumes: Overweight
Price Target: $250
Current: $208.43
Upside: +19.94%
Sana Biotechnology
Jul 3, 2025
Assumes: Overweight
Price Target: $12
Current: $4.35
Upside: +176.18%
TScan Therapeutics
Mar 14, 2025
Assumes: Overweight
Price Target: $10
Current: $2.20
Upside: +354.55%
Invivyd
Nov 20, 2024
Maintains: Overweight
Price Target: $9.5 → $3.55
Current: $1.88
Upside: +88.83%